🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 1 día
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 13/03/2009 | 29,26 | 29,60 | 28,46 | 29,10 | -0,55% | 3,90% | 1.730.900 |
| 12/03/2009 | 27,07 | 29,53 | 27,00 | 29,26 | +7,77% | 9,35% | 2.004.000 |
| 11/03/2009 | 28,57 | 29,02 | 27,05 | 27,15 | -4,54% | 6,90% | 2.259.000 |
| 10/03/2009 | 27,45 | 28,75 | 27,12 | 28,44 | +5,49% | 5,94% | 2.562.700 |
| 09/03/2009 | 27,55 | 28,25 | 26,89 | 26,96 | -2,92% | 4,94% | 1.942.800 |
| 06/03/2009 | 28,04 | 28,59 | 27,56 | 27,77 | -0,68% | 3,67% | 2.977.900 |
| 05/03/2009 | 28,17 | 28,69 | 27,48 | 27,96 | -0,25% | 4,30% | 2.733.400 |
| 04/03/2009 | 29,14 | 29,39 | 27,44 | 28,03 | +0,25% | 6,69% | 3.649.700 |
| 03/03/2009 | 27,23 | 28,48 | 27,23 | 27,96 | +2,68% | 4,59% | 3.206.300 |
| 02/03/2009 | 28,86 | 29,16 | 26,67 | 27,23 | -9,65% | 8,63% | 3.768.200 |
| 27/02/2009 | 32,46 | 32,72 | 29,56 | 30,14 | -8,67% | 9,74% | 5.051.200 |
| 26/02/2009 | 33,13 | 33,46 | 32,18 | 33,00 | -0,18% | 3,86% | 3.802.000 |
| 25/02/2009 | 33,43 | 34,25 | 32,76 | 33,06 | -1,55% | 4,46% | 2.433.900 |
| 24/02/2009 | 33,15 | 33,68 | 32,81 | 33,58 | +2,10% | 2,62% | 2.325.800 |
| 23/02/2009 | 33,18 | 33,50 | 32,82 | 32,89 | -0,51% | 2,05% | 2.271.400 |
| 20/02/2009 | 33,34 | 33,80 | 32,88 | 33,06 | -1,90% | 2,76% | 2.636.500 |
| 19/02/2009 | 33,10 | 34,34 | 33,00 | 33,70 | +3,50% | 4,05% | 4.705.600 |
| 18/02/2009 | 33,27 | 33,35 | 32,10 | 32,56 | -1,63% | 3,76% | 1.358.100 |
| 17/02/2009 | 32,52 | 33,49 | 32,36 | 33,10 | -0,57% | 3,47% | 1.746.800 |
| 13/02/2009 | 33,30 | 33,70 | 32,73 | 33,29 | +0,00% | 2,91% | 1.314.500 |
| 12/02/2009 | 31,56 | 33,29 | 31,46 | 33,29 | +4,42% | 5,80% | 1.720.600 |
| 11/02/2009 | 31,62 | 32,26 | 31,27 | 31,88 | +1,24% | 3,13% | 1.454.600 |
| 10/02/2009 | 33,20 | 33,20 | 30,66 | 31,49 | -6,08% | 7,65% | 3.578.600 |
| 09/02/2009 | 34,67 | 34,80 | 32,94 | 33,53 | -4,20% | 5,36% | 2.141.400 |
| 06/02/2009 | 35,01 | 35,97 | 34,59 | 35,00 | +3,06% | 3,94% | 2.794.800 |
| 05/02/2009 | 33,10 | 34,20 | 32,91 | 33,96 | +1,71% | 3,90% | 1.490.400 |
| 04/02/2009 | 32,89 | 34,17 | 32,89 | 33,39 | +0,57% | 3,89% | 1.432.700 |
| 03/02/2009 | 32,79 | 33,24 | 31,99 | 33,20 | +1,37% | 3,81% | 1.845.500 |
| 02/02/2009 | 32,85 | 32,97 | 32,29 | 32,75 | -0,91% | 2,07% | 2.389.300 |
| 30/01/2009 | 33,67 | 33,84 | 32,98 | 33,05 | -1,99% | 2,55% | 1.948.500 |